Troponin for Acute Coronary Syndromes

Thomson JDR Mackintosh AF Barth JH . Troponin for acute coronary syndromes: has NICE got it right? Ann Clin Biochem 2002; 39: 194–5.

The GUSTO IV-ACS investigators. Effect of glycoprotein llb/llla receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–24.

The PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein llb/llla receptor with tirofiban in unstable angina and non q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–97.

Mahaffey KW Roe MT Dyke CK Newby LK Kleiman NS Connolly P . Misreporting of myocardial infarction endpoints: results of adjudication by a central clinical events committee in the PARAGON B trial. Second platelet llb/llla antagonist for the reduction of acute coronary syndrome events in a global organisation network trial. Am Heart J 2002; 143: 242–8.

Boersma E Harrington RA Moliterno DJ White H Theroux P Van De Werf F . Platelet glycoprotein llb/llla inhibitors in acute coronary syndromes; a meta analysis of all major randomised clinical trials. Lancet 2002; 359: 189–98.

Wald DS Murphy CF Quiney J Reid CJ . How useful is troponin T in deciding the management of patients admitted to hospital with chest pain? Br J Cardiol 2000; 7: 272–6.

Collinson PO . Cardiac markers into the new millennium. Ann Clin Biochem 2000; 37: 109–13.